{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:02:47Z","timestamp":1790744567969,"version":"4.1.0"},"reference-count":51,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Patients with relapsed and\/or refractory (R\/R) follicular lymphoma (FL) and mantle cell lymphoma (MCL) have a poor prognosis with anticipated short progression-free and overall survivals. Two CD19-directed chimeric antigen receptor T-cell (CAR T) therapies are approved in the United States for R\/R FL, namely, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel. The results of ZUMA-5 and ELARA studies led to the approval of axi-cel and tisagenlecleucel, respectively, after demonstrating high overall (ORR) and complete response (CR) rates in this high-risk population of FL patients who had received a median of 3 (range\u2009=\u20092\u20134) and 4 (range\u2009=\u20092\u201313) prior lines of therapies, respectively. For instance, the ORR for ZUMA-5 was 94% (CR\u2009=\u200979%), and for ELARA, it was 86% (CR\u2009=\u200969.1%). Pertaining to MCL, brexucabtagene autoleucel is approved for R\/R MCL based on results of the ZUMA-2 study. In the latter study, despite the fact that all R\/R MCL patients had been exposed to prior Bruton\u2019s tyrosine kinase inhibitors, the reported ORR was 91%, with 68% achieving a CR. These results undoubtedly demonstrate a strong efficacy of CAR T therapy in both R\/R FL and MCL; yet, one must acknowledge the relatively short follow-up time of all aforementioned studies. Thus, longer follow-up showing durability of responses and long-term safety is definitely needed.<\/jats:p>","DOI":"10.1177\/20406207221142133","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T06:46:47Z","timestamp":1671173207000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma"],"prefix":"10.1177","volume":"13","author":[{"given":"Razan","family":"Mohty","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, 4500 San Pablo Road, Mangurian Bldg, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"bibr1-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"bibr2-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"bibr3-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"bibr4-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"bibr5-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"bibr6-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"bibr7-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"bibr8-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"bibr9-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"bibr10-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.251"},{"key":"bibr11-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198211113072002"},{"key":"bibr12-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"bibr13-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"bibr14-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"bibr15-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"bibr16-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"bibr17-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614598"},{"key":"bibr18-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010263"},{"key":"bibr19-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22617"},{"key":"bibr20-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314583"},{"key":"bibr21-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00145-5"},{"key":"bibr22-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"bibr23-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.771"},{"key":"bibr24-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01192-8"},{"key":"bibr25-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31264"},{"key":"bibr26-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31374"},{"key":"bibr27-20406207221142133","unstructured":"Gormley N. FDA introductory comments. Oncologic drugs advisory committee meeting 2022. FDA, U.S. Food and Drug Administration, https:\/\/www.fda.gov\/media\/157837\/download (2022, accessed 13 September 2022)."},{"key":"bibr28-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"bibr29-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000905"},{"key":"bibr30-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"bibr31-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148473"},{"key":"bibr32-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145025"},{"key":"bibr33-20406207221142133","first-page":"1","volume":"42","author":"Kumar A","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"bibr34-20406207221142133","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling M","year":"2005","journal-title":"Blood"},{"key":"bibr35-20406207221142133","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine O","year":"2016","journal-title":"Lancet"},{"key":"bibr36-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"bibr37-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"bibr38-20406207221142133","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2021-150181","volume":"138","author":"Hermine O","year":"2021","journal-title":"Blood"},{"key":"bibr39-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"bibr40-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1002\/hon.61_2880"},{"key":"bibr41-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15411"},{"key":"bibr42-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"bibr43-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7518"},{"key":"bibr44-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.521"},{"key":"bibr45-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006922"},{"key":"bibr46-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e19583"},{"key":"bibr47-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136158"},{"key":"bibr48-20406207221142133","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S202015"},{"key":"bibr49-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2019.05.005"},{"key":"bibr50-20406207221142133","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14870"},{"key":"bibr51-20406207221142133","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030164"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207221142133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207221142133","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207221142133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:16:24Z","timestamp":1777590984000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207221142133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":51,"alternative-id":["10.1177\/20406207221142133"],"URL":"https:\/\/doi.org\/10.1177\/20406207221142133","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"20406207221142133"}}